The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
The funding round was led by UTokyo Innovation Platform and will be used to expand operations and accelerate product development.
"Scenes we know from films, from Iron Man to Star Trek, are becoming closer to reality than ever. At VividQ, we are on a mission to bring holographic displays to the world for the first time. Our solutions help bring innovative display products to the automotive industry, improve AR experiences, and soon will change how we interact with personal devices, such as laptops and mobiles."
Cambridge Enterprise led the seed financing, which includes backing from Parkwalk, New Grounds, and R42 Group.
"Many researchers would like to get molecular binding data more conveniently and more frequently to guide them through a drug development project. HexagonFab aims to address this need with the Bolt. This investment will enable us to bring our game-changing product to the market. We look forward to the months ahead working closely with our lead customers,"
— Christoph von Bieberstein, Founder and Commercial Director
